6505--Philadelphia VA Medical Center | Lab Supplies - Radiopharm

Where this opportunity stands

Every notice posted under solicitation 36C24426Q0851 in this department, oldest first.

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

• Answer the notice: this is when the requirement can still be shaped.
• Contact the contracting officer named on the notice.
• Check who won similar work; they are the likely bidders.

Who won similar work

22 award notices on SAM.gov in the last 24 months. Matched by: Same office (244-NETWORK CONTRACT OFFICE 4 (36C244)), same product/service code (PSC) 6505 and NAICS 325412.

Single-winner award sizes (22): middle half $467K to $2.5M, median $1.2M; range $121K to $4.6M.

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

• Oct 2, 2026CARDINAL HEALTH 414, LLC$4.6M6505--Lab Supplies | Radiopharm | New 5 year consolidation Lebanon & Pittsburgh - Illuccix | 595 and 646 | EDA: 10/01/2026 VLD | Status: moved to collaboration, once actionable will be assigned to ChrMateriality: <0.01% of $CAH revenue (Low) SEC
• Oct 1, 2026CARDINAL HEALTH 414, LLC$638K6505--Fluorodeoxyglucose (FDG) RadiopharmaceuticalMateriality: <0.01% of $CAH revenue (Low) SEC
• Sep 2, 2026CARDINAL HEALTH 414, LLC$3.6M6505--Lab Supplies | Radiopharm | 5-Year Indefinite Delivery/Indefinite Quantity (IDIQ) | VA Pittsburgh Healthcare SystemMateriality: <0.01% of $CAH revenue (Low) SEC
• Jul 25, 2026CARDINAL HEALTH 414, LLC$3.6M6505--Lab Supplies | Radiopharm | 5-Year Indefinite Delivery/Indefinite Quantity (IDIQ) | VA Pittsburgh Healthcare SystemMateriality: <0.01% of $CAH revenue (Low) SEC
• Apr 2, 2026CARDINAL HEALTH 414, LLC$2.7M6505--Intent to Sole Source | Xofigo RA-223 | Brand Name Only 5 YR-Indefinite Delivery/Indefinite Quantity (IDIQ) Multiple Stations (646, 642, 595)Materiality: <0.01% of $CAH revenue (Low) SEC
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$249K6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$127K6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$2.0M6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$3.4M6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)
• Feb 12, 2026EXELAN PHARMACEUTICALS INC$1.0M6505--Specialty Pharmaceutical Lenalidomide FAR Part 8 FSS - LPTANo listed company matched (Materiality N/A)

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.